China’s Abogen advancing mRNA vaccine for COVID-19, pipeline with $700M series C
Record-setting round, crossover investors and new CFO could position Abogen for a listing
A record-setting venture round backed by crossover investors and the addition of Chelsea Zhang as CFO could position Suzhou company for a near-term public listing.
Aug 19, 2021 | 11:56 PM GMT
The $700 million series C funding for mRNA